- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04530227
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
A Pilot Study of Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This trial will evaluate the safety and efficacy of camrelizumab in combination with chemotherapy, followed by camrelizumab alone after 4-6 cycles of combination in participants with medically inoperable stage I or IIA non-small cell lung cancer (NSCLC). The primary objective of this pilot study is to determine the Camrelizumab plus chemotherapy improves progression-free survival (PFS) . All the efficacy and safety are assessed by investigator : 1) response rate (ORR), 2) disease control rate (DCR); 3) overall survival (OS), 4) PFS rate of 1-year, 2-year, and 5-year; and 5) OS rate of 1-year, 2-year, and 5-year.
Explore objective is potential biomarker associated with efficacy.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Changli Wang, PhD
- Número de teléfono: 6417 86-22-23340123
- Correo electrónico: wangchangli@medmail.com.cn
Copia de seguridad de contactos de estudio
- Nombre: Lianming Zhang, PhD
- Número de teléfono: 6417 86-22-23340123
Ubicaciones de estudio
-
-
-
Tianjin, Porcelana, 300060
- Reclutamiento
- Tianjin Medical University Cancer Institute and Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients aged ≥18 years, male and female are not limited;
- Patients with ECOG score of 0-1;
- Life expectancy ≥12 weeks;
- Patients must have histologically- or cytologically-documented NSCLC (according to 2015 WHO Classification);
- Patients with stage I - IIA (T1-T2bN0M0, tumor size ≤ 50mm) confirmed by radiographic;and medical inoperable, unable to undergo thoracic surgery, or refusing to surgery (according to the eighth edition of TNM staging);
- Patients with measurable target lesions according to the RECIST 1.1 standard;
- Patients have not received prior treatment for their NSCLC, including radiotherapy, chemotherapy, surgery and target drugs;
- Can provide tumor tissue;
- Adequate organ and marrow function;
- Fertile female were required to have a serum or urine pregnancy test within 72 hours before the start dose of study medication and the result has been negative;If female of childbearing potential, is willing to use adequate contraception for the course of the study through 90 days after the last dose of study medication; if male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 90 days after the last dose of study medication;
- Provision of signed ICF.
Exclusion Criteria:
- Known any distance metastases;
- Patients with known EGFR gene mutation or ALK fusion mutation;
- Patients with any active autoimmune disease or history of autoimmune disease;
- Patients with innate or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or co-infection with hepatitis B and hepatitis C;
- Subjects requiring systemic treatment with corticosteroids (> 10 mg / day of prednisone or its equivalent) or other immunosuppressants within 14 days prior to the first administration;
- Patient must not have received a live, attenuated vaccine within 4 weeks prior to the first administration;
- Any therapy for NSCLC treatment;
- Patients with other malignant tumors in the past 5 years;
- Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiologic pneumonia, drug-induced pneumonia and active pneumonia confirmed by imaging;
- Patients with cardiac insufficiency;
- Routine urine test indicated that urine protein was >= (+ +), or 24-hour urine protein was >= 1g, or severe liver and kidney dysfunction;
- Patients with severe infection or fever of unknown origin >38.5 ℃ within 4 weeks prior to the first administration;
- Patients with known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures;
- Known allergies, hypersensitivity, or intolerance to camrelizumab or its excipients or to pemetrexed or to nab-paclitaxel;
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results,or the patient is unlikely to comply with study procedures, restrictions, and requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Camrelizumab combined with chemotherapy
Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy. Interventions: Biological: Camrelizumab |
quimioterapia
Otros nombres:
PD-1
Otros nombres:
chemotherapy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free Survival (PFS)
Periodo de tiempo: up to approximately 3 years
|
PFS is determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
|
up to approximately 3 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Survival (OS)
Periodo de tiempo: up to approximately 5 years
|
OS is defined as the first date of treatment to date of death from any causes.
|
up to approximately 5 years
|
Objective response rate (ORR)
Periodo de tiempo: up to approximately 1 years
|
ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 by investigator.
|
up to approximately 1 years
|
Disease Control Rate (DCR)
Periodo de tiempo: up to approximately 3 years
|
DCR is defined as the percentage of patients who have achieved complete response and partial response per RECIST 1.1 by investigator..
|
up to approximately 3 years
|
Adverse Events (AEs)
Periodo de tiempo: up to 18 months
|
The number of participants experiencing an AE will be assessed.
|
up to 18 months
|
SLP a los 12 meses (PFS12)
Periodo de tiempo: hasta un máximo de 12 meses
|
La PFS se calculará utilizando los métodos de límite de producto de Kaplan-Meier.
|
hasta un máximo de 12 meses
|
PFS at 24 months (PFS24)
Periodo de tiempo: up to maximum 24 months
|
PFS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 24 months
|
PFS at 5 years
Periodo de tiempo: up to maximum 5 years
|
PFS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 5 years
|
OS a los 12 meses (OS12)
Periodo de tiempo: hasta un máximo de 12 meses
|
La OS se calculará utilizando los métodos de límite de producto de Kaplan-Meier.
|
hasta un máximo de 12 meses
|
OS a los 24 meses (OS24)
Periodo de tiempo: hasta un máximo de 24 meses
|
La OS se calculará utilizando los métodos de límite de producto de Kaplan-Meier.
|
hasta un máximo de 24 meses
|
OS at 5 years
Periodo de tiempo: up to maximum 5 years
|
OS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 5 years
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Antagonistas del ácido fólico
- Paclitaxel
- Paclitaxel unido a albúmina
- Pemetrexed
Otros números de identificación del estudio
- MA-NSCLC-II-007
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Pemetrexed
-
Boehringer IngelheimTerminadoCarcinoma de pulmón de células no pequeñasJapón
-
Shanghai Shengdi Pharmaceutical Co., LtdAún no reclutandoCáncer de pulmón de células no pequeñas no escamosoPorcelana
-
Rongjie TaoNational Natural Science Foundation of ChinaDesconocidoMetástasis cerebralesPorcelana
-
Northwestern UniversityNational Cancer Institute (NCI)DesconocidoLinfoma | Tumores cerebrales y del sistema nervioso central | Cáncer metastásicoEstados Unidos
-
PfizerTerminadoCarcinoma de pulmón de células no pequeñasEstados Unidos, Alemania, Italia
-
Eli Lilly and CompanyTerminadoCáncer de pulmón de células no pequeñas metastásico | Neoplasia de pulmón de células no pequeñas no escamosas | Cáncer de pulmón de células no pequeñas en estadio IIIBReino Unido, Suecia
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminadoCarcinoma de pulmón de células no pequeñasNoruega
-
Ain Shams UniversityDesconocido
-
Spanish Lung Cancer GroupTerminadoCarcinoma De Pulmón De Células No PequeñasEspaña
-
Threshold PharmaceuticalsEMD SeronoTerminadoCáncer de pulmón de células no pequeñasEstados Unidos, Alemania, España, Polonia, Grecia, Chequia, Hungría, Italia, Rumania, Federación Rusa